TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time between induction of prostaglandins and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Primary patent rate of AV fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Passing accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passing speed by Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shooting speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunogenicity of Purified Vero Rabies Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resolution periapical radiolucency (Clinical evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution periapical radiolucency (Radiographic evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of bone width from baseline measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Differentiation of malignancy in duct involved IPMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: preference rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Vertical Self-Motion Perception Reaction Time (VSMPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device and procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Medical residents' performance in maximal barrier precaution (MBP) technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: diuretics' use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Amount of skeletal and dental expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of dental inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echymosis around the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of correct diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in deportment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in rotator cuff voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in specific rotator cuff muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ALSFRS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Raymond Class I Complete Obliteration at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Neurological Deaths or Major Ipsilateral Strokes at 12 Months Post Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Left Ventricular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycocalyx Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcific bridge formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant-Murley shoulder score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Multidimensional Anxiety Scale for Children (MASC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Corneal measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potentially Inappropriate Proton Pump Inhibitors Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Striatal [18F]-DOPA uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps Femoris Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Purchase intent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a Cocaine-Positive Urine Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Time needed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of modified global rating scores (GRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Likert score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rebound esthesiometer operating threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebound esthesiometer operating parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Losses of postural and attentional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected QT (QTc) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to primary clinical endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scores of inflammation in UC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Experiencing a Major Depressive Episode Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Treatment Response Measured Using the Montgomery Asberg Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophizing Scale (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity assessed by PRNT50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of increased frequency of dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Granulation Tissue on the Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Morbi-mortality for mother and child
Endpoint domain: Mortality/survival
Primary endpoint: Confirmation of the LOR with epidurally located Tuohy needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relapse-free Survival (RFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in physiological sexual arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term change in physiological sexual arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to study protocol at 3 months after spine surgery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adherence rate to study protocol at 6 months after spine surgery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: GI Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cerebral saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic Responses (Rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic Responses (Active)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK (AUC0-7d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of organ donations after brain death
Endpoint domain: Mortality/survival
Primary endpoint: Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AIDS risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of nicotine in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic effectiveness of 18F-FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Serum Concentration Time Curve From Zero to Day 7 (AUC0-7) of Obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration Versus Time Curve From 0 to Day 21 (AUC0-21) of Obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA negative swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of ED and Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of Life in Dementia (QUALI-DEM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Any and Grade 3 Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Global Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in BPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Live Assessment of Satisfaction With the Grafts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of Tip Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of Use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change from Baseline in Low-density Lipoprotein-Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause
Endpoint domain: Adverse events/effects
Primary endpoint: IIEF-5 point
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Percent Change in SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive PCR
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent hemarthroses rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Enzymatic activity of salivary amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Low-Density Lipoprotein (LDL)-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in maxillary central incisor sagittal dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maxillary central incisor vertical dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maxillary central incisor angular dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maxillary anterior transverse dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Reporting Dysphagia/Severe Dysphagia Through EAT-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Reporting Abnormal Vocal Handicap Measured by the VHI-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Disability Index (NDI) Mean Percentage Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median Visual Analog Scale Pain Score for Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Reporting Mild/Moderate/Severe Dysphagia Measured With Bazaz Dysphagia Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Urinary Tract Infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in postprandial glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in postprandial insulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrence of the hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: necrosis of the edges of the wound
Endpoint domain: Adverse events/effects
Primary endpoint: Change in VISA-P score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell (RBC) -Transfusion Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute complications during insertion of regional anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Complete and partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from atrial fibrillation and atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical treatment success of stricture or leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic stricture diameter in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With hPV19 Drug-Related Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Types and incidence of Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Types and incidence of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change of myocardial blood flow at rest and at stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of myocardial blood flow reserve at rest and at stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-help groups attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-help groups involvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of PET/MR vs. PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PET/MR vs. PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analogue Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: T-lymphocyte cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ocular Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life related to Constipation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite outcome of Stroke, MI, and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: AF Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Occult Blood Test (FOBT) completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Number of MII oocytes per number of oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of placental-derived MPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers (PlGF, VEGF, sFLT-1, sEng)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterograde PCI success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: STDs prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Device related major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success of the Tandem Snare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Confirmed Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Auto-Inflammatory Diseases Activity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of serum vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfer of L. rhamnosus GG (estimated CFU counts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the score of allergic rhinitis symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of severe thrombocytopenia (<30G/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of hemorrhagic complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ITP treatment modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes